Pennant Investors, LP Sage Therapeutics, Inc. Transaction History
Pennant Investors, LP
- $367 Million
- Q2 2024
A detailed history of Pennant Investors, LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Pennant Investors, LP holds 17,500 shares of SAGE stock, worth $122,325. This represents 0.05% of its overall portfolio holdings.
Number of Shares
17,500
Previous 17,500
-0.0%
Holding current value
$122,325
Previous $327,000
41.9%
% of portfolio
0.05%
Previous 0.08%
Shares
1 transactions
Others Institutions Holding SAGE
# of Institutions
218Shares Held
48.2MCall Options Held
854KPut Options Held
195K-
Vanguard Group Inc Valley Forge, PA6.42MShares$44.9 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$38.3 Million0.99% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$36.5 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$31.2 Million0.81% of portfolio
-
State Street Corp Boston, MA2.47MShares$17.3 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $415M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...